Alkermes Submits Vivitrol Complete Response
This article was originally published in The Pink Sheet Daily
You may also be interested in...
Alkermes/Cephalon expect to launch the renamed once-monthly naltrexone injection in the second quarter.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.